Cointime update: Eli Lilly said the combination of Taltz and Zepbound met the primary endpoint in a 36-week clinical trial. The trial evaluated the two drugs together over the 36-week period. No further efficacy or safety data from the study were disclosed in the announcement.
Eli Lilly’s Taltz Plus Zepbound Meets Primary Endpoint in 36-Week Trial
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
9m ago
Ackman Questions Nvidia Board’s Handling of Jensen Huang Departure
1h ago
Strategy’s STRC Perpetual Preferred Slips ~4% Below Peg to $96.35
2h ago
StoneX cuts Bitdeer price target to $15, keeps Buy rating
2h ago
Dow Falls 1% as US Stocks Extend Losses
3h ago
Nasdaq Opens Up 0.7% as AI-Linked Stocks Rally on Nvidia Outlook
3h ago
UBS Cuts Nvidia Price Target to $220 from $240